David Mott
Chairman of the Board
Biopharmaceutical
3-V BIOSCIENCES
United States of America
Biography
David M. Mott joined NEA in September 2008 as a General Partner focused on biopharmaceutical investments. Prior to joining NEA, he was President and Chief Executive Officer of MedImmune, subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. Dave joined MedImmune in 1992 and served in roles of increasing responsibility including Chief Operating Officer, Chief Financial Officer, President and Chief Executive Officer as the company grew from a venture-backed startup (founded in 1988) into one of the top five biotechnology companies in the world. Ultimately, he initiated and executed the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion
Research Interest
biopharmaceuticals
